Evidence map›Paper›PMID 39140090›Full record

ArticleFrontiers in ophthalmology2024

High-throughput ultrastructural analysis of macular telangiectasia type 2.

Charles L Zucker, Paul S Bernstein, Richard L Schalek, Jeff W Lichtman, John E Dowling

Abstract read
In one paragraph

Article in Frontiers in ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Macular telangiectasia type 2: An update.The Journal of international medical research · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Charles L ZuckerDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA, United States.
Paul S BernsteinDepartment of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT, United States.
Richard L SchalekDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA, United States.
Jeff W LichtmanDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA, United States.
John E DowlingDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA, United States.

Funding

Zooming into the fish's brain-What is really going on! Connectomics analysis of larval zebrafish.U19NS104653 · NINDS · HARVARD UNIVERSITY · PI JOSHUA T VOGELSTEIN · 2017 to 2026
$39.4M
Res Support CoreP50MH094271 · NIMH · HARVARD UNIVERSITY · PI HENSCH, TAKAO K · 2011 to 2022
$18.6M
University of Utah, Core Vision Research GrantP30EY014800 · NEI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jun Yang · 2005 to 2026
$14.6M
Biochemistry and Pharmacology of the Macular CarotenoidsR01EY011600 · NEI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI BERNSTEIN, PAUL STEVEN · 2004 to 2025
$7.7M
A Facility to Generate Connectomics InformationU24NS109102 · NINDS · HARVARD UNIVERSITY · PI LICHTMAN, JEFF W · 2018 to 2023
$6.5M
Ultrastructural Analysis of a Form of Macular Degeneration - Macular TelangiectasiaR21EY030255 · NEI · HARVARD UNIVERSITY · PI DOWLING, JOHN E · 2020 to 2022
$561k
BIOCHEMISTRY AND PHARMACOLOGY OF THE MACULAR CAROTENOIDSR29EY011600 · NEI · UNIVERSITY OF UTAH · PI BERNSTEIN, PAUL STEVEN · 1997 to 2001
$209k
NEI NIH HHS P30 EY014800NEI NIH HHS R01 EY011600NEI NIH HHS R21 EY030255NEI NIH HHS R29 EY011600NIMH NIH HHS P50 MH094271NINDS NIH HHS U19 NS104653NINDS NIH HHS U24 NS109102
6 · The paper itself

Abstract

Introduction: Macular Telangiectasia type 2 (MacTel), is an uncommon form of late-onset, slowly-progressive macular degeneration. Associated with regional Müller glial cell loss in the retina and the amino acid serine synthesized by Müller cells, the disease is functionally confined to a central retinal region - the MacTel zone. Methods: We have used high-throughput multi-resolution electron microscopy techniques, optimized for disease analysis, to study the retinas from two women, mother and daughter, aged 79 and 48 years respectively, suffering from MacTel. Results: In both eyes, the principal observations made were changes specific to mitochondrial structure both outside and within the MacTel zone in all retinal cell types, with the exception of those in the retinal pigment epithelium (RPE). The lesion areas, which are a hallmark of MacTel, extend from Bruch's membrane and the choriocapillaris, through all depths of the retina, and include cells from the RPE, retinal vascular elements, and extensive hypertrophic basement membrane material. Where the Müller glial cells are lost, we have identified a significant population of microglial cells, exclusively within the Henle fiber layer, which appear to ensheathe the Henle fibers, similar to that seen normally by Müller cells. Discussion: Since Müller cells synthesize retinal serine, whereas retinal neurons do not, we propose that serine deficiency, required for normal mitochondrial function, may relate to mitochondrial changes that underlie the development of MacTel. With mitochondrial changes occurring retina-wide, the question remains as to why the Müller cells are uniquely susceptible within the MacTel zone.

Indexed as

electron microscopyMacTelmacular degenerationmacular telangiectasia type 2microgliamitochondriaMüller cellserine

Identifiers

PMID39140090
PMCPMC11319912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.